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ABSTRACT 110 
The evolutionary processes that drive universal therapeutic resistance in adult patients with 111 
diffuse glioma remain unclear. Here, we analyzed temporally separated DNA sequencing data 112 
and matched clinical annotation from 222 patients with glioma. Through mutational and copy 113 
number analyses across the three major subtypes of diffuse glioma, we observed that driver 114 
genes detected at initial disease were retained at recurrence, while there was little evidence of 115 
recurrence-specific gene alterations. Treatment with alkylating-agents resulted in a 116 
hypermutator phenotype at different rates across glioma subtypes, and hypermutation was not 117 
associated with differences in survival. Acquired aneuploidy was frequently detected in recurrent 118 
gliomas characterized by presence of an IDH mutation but without 1p/19q codeletion and further 119 
converged with acquired cell cycle alterations and poor outcomes. We show that the clonal 120 
architecture of each tumor remains similar over time and that absence of clonal selection was 121 
associated with increased survival. Finally, we did not observe differences in immunoediting 122 
levels between initial and recurrent glioma. Our results collectively argue that the strongest 123 
selective pressures occur early during glioma development and that current therapies shape this 124 
evolution in a largely stochastic manner. 125 
  126 
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INTRODUCTION 127 
Diffuse glioma is the most common malignant brain tumor in adults and invariably relapse 128 
despite treatment with surgery, radiotherapy, and chemotherapy. The molecular landscape of 129 
glioma at diagnosis has been extensively characterized 1-7. While these efforts have led to the 130 
identification of driver genes and clinically relevant subtypes8,9, it is unknown how the glioma 131 
genetic landscape evolves over time and in response to therapy.  132 
Intratumoral heterogeneity is a well-recognized characteristic of gliomas and results from 133 
selective pressures such as a limited availability of nutrients, clonal competition, and 134 
treatment10-13. Tumors are thought to circumvent these growth bottlenecks via dynamic 135 
competition of subclones resulting in the most favorable environment for tumor sustenance14. 136 
Recent studies have suggested that stochastic changes in clone frequency (i.e. neutral 137 
evolution) and immunogenic surveillance may further contribute to the observed intratumoral 138 
heterogeneity15 16. An understanding of evolutionary dynamics at multiple time points is needed 139 
to develop strategies aimed at delaying or preventing the onset of tumor progression. 140 
To investigate clonal dynamics over time and in response to therapeutic pressures, we 141 
established the Glioma Longitudinal Analysis (GLASS) Consortium. GLASS is a community-142 
driven effort that seeks to overcome the logistical challenges in constructing adequately 143 
powered longitudinal genomic glioma datasets by pooling datasets from patients treated at 144 
institutions worldwide 17. We have analyzed longitudinal profiles across the three molecular 145 
glioma subtypes to identify the molecular processes active at initial and recurrent time points. 146 
These analyses identified few common features of glioma evolution across subtypes, and 147 
instead pointed toward highly variable and patient-specific trajectories of genomic alterations. 148 
RESULTS 149 
GLASS cohort  150 
We pooled existing and newly generated longitudinal DNA sequencing datasets from 288 151 
patients treated at 35 hospitals (Supplementary Table 1, Extended Data Fig. 1).  After applying 152 
quality filters, tumor samples from 222 patients with high-quality data in at least two time points 153 
were classified according to molecular markers into three major glioma subtypes: 1. IDH-mutant 154 
and chromosome 1p/19q co-deleted (IDHmutant-codel; n = 25) 2. IDH-mutant without 155 
chromosome 1p/19q codeletion (IDHmutant-noncodel; n = 63) and 3. IDH wild type (IDHwt; n = 156 
134), in alignment with the World Health Organization classification of Central Nervous System 157 
tumors 8,9. For each patient we selected two time-separated tumor samples, henceforth initial 158 
and recurrence, for further analysis.  159 
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Mutational burdens and processes over time 160 
We first evaluated temporal changes in mutational burden and processes to understand general 161 
patterns of glioma evolution. Mutation burdens in initial tumors were comparable with previously 162 
reported rates 4,5,18. 2.20 mutations (single-nucleotide variants and small insertions/deletions) 163 
per Megabase (Mutations/Mb) for IDHmutant-codels; 2.52 Mutations/Mb for IDHmutant-164 
noncodels; and 2.85 Mutations/Mb for IDHwt glioma (Fig. 1a; Extended Data Fig. 2a). Excluding 165 
DNA hypermutation cases (> 10 Mutations/Mb, n = 35), the mutation burden increased after 166 
recurrence in 70% of the cohort (Extended Data Fig. 2a). To study changes during tumor 167 
progression, we separated mutations into three fractions: initial only, recurrence only, or shared. 168 
Interestingly, private fraction but not shared fraction mutation burdens were comparable 169 
between subtypes (Extended Data Fig. 2b). Patient age at diagnosis was significantly 170 
associated with the shared mutational burden and to a lesser extent the mutation burden private 171 
to the initial tumor (Extended Data Fig. 2c). On average, tumors with longer time to recurrence 172 
had slightly higher mutation burdens (Extended Data Fig. 2d).  173 
These fraction-specific differences in mutation burden suggested that the activity of 174 
distinct mutational processes may also be time-dependent. We therefore classified mutations in 175 
each fraction according to the Catalogue of Somatic Mutations in Cancer (COSMIC) signature 176 
database19. As expected, signature activity was closely related to subtype and fraction (Fig. 1b, 177 
Extended Data Fig. 3a). Signature 1 (aging) was nearly always the dominant signature amongst 178 
shared mutations in IDHwt tumors, whereas the shared fraction in IDHmut-noncodel and 179 
IDHmut-codel tumors - tumor subtypes associated with a younger age of diagnosis - additionally 180 
showed a strong presence of signature 16 (unknown etiology). Signatures 3 (double strand 181 
break repair) and 15 (mismatch repair) along with signature 8 (unknown etiology) were mostly 182 
confined to the private fractions, suggesting that these processes were of lesser importance to 183 
tumor maintenance than those associated with aging.  184 
Treatment of glioma includes alkylating agents that can induce post-treatment 185 
hypermutation20-22. We observed enrichment of the associated signature 11 in recurrent tumors 186 
with a mutational load exceeding 10 Mutations/Mb and treated with alkylating agents (Fig. 1a, 187 
Extended Data Fig. 3b). Treatment-associated hypermutation occurred most frequently among 188 
IDHmutant-noncodels (47%), followed by IDHmutant-codels (25%), and IDHwt gliomas (16%) 189 
(Fig. 1c). The difference in the proportion of hypermutation events was significantly different 190 
between the three glioma subtypes (Fisher’s exact-test P = 2.0e-03), suggesting that IDHmutant 191 
noncodels are most sensitive to developing a hypermutator phenotype 23. 192 
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Treatment-induced hypermutation has been associated with disease progression22. We 193 
did not find overall survival differences between alkylating agent-treated hypermutators and 194 
alkylating agent-treated non-hypermutators independent of age, subtype, and MGMT 195 
methylation status (Fig. 1d, Supplementary Table 2a-b). In order to further assess the 196 
pathogenicity of acquired mutations, we studied their clonality24. Newly acquired clonal 197 
mutations have penetrated most of the tumor (i.e., a selective sweep) between initial and 198 
recurrence and mark clonal expansion 25. Conversely, acquired subclonal mutations are less 199 
prevalent, and therefore less likely to drive disease progression. Previous reports have 200 
suggested that alkylating agent-associated mutations hypermutation are frequently clonal26. We 201 
found that in 48% of hypermutated tumors a majority of the recurrence-only mutations were 202 
clonal, potentially reflecting cases where a selective sweep occurred (Extended Data Fig. 4a). 203 
However, IDHmut-noncodel hypermutators with predominantly clonal mutations did not show 204 
differences in survival compared with those harboring predominantly subclonal mutations (log-205 
rank test P = 0.38, Extended Data Fig. 4b). Alkylating agents such as temozolomide prolong 206 
survival of adult patients with glioma27,28. Our results show that treatment-induced 207 
hypermutation is common across subtypes and does not associate with a reduced overall 208 
survival supporting the noted benefit of alkylating agent therapy.  209 
Selective pressures during glioma evolution  210 
Environmental and treatment-induced pressures may drive changes in clonal architecture at 211 
recurrence. To evaluate selection over time we clustered copy number changes and mutations 212 
based on their cancer cell fraction (CCF). CCF values represent the fraction of cancer cells 213 
harboring a given alteration and reflect the relative timing of events, since alterations that are 214 
present in a subset of cancer cells likely occurred later than events present in all cancer cells 215 
(Fig. 2a). Most tumors (84%) demonstrated a mutational cluster with CCF > 50% that persisted 216 
from the initial tumor into recurrence, likely reflecting the tumor trunk and harboring the tumor-217 
initiating driver mutations (Fig. 2b, Extended Data Fig. 5a)29. To determine changes in clonal 218 
dominance over time we ranked clusters within each sample by their CCF and found similarities 219 
in clonal architecture throughout the course of disease (Kendall rank correlation, tau = 0.20, P = 220 
3.76E-24, Fig. 2b, Extended Data Fig. 5b-d). These results suggested that the clonal structure 221 
at initial disease mostly persisted into recurrence.  222 
To deepen our assessment of selective pressures, we evaluated selection in initial and 223 
recurrent tumors by determining the normalized ratio between non-synonymous and 224 
synonymous mutations (dNdScv). Higher ratios (> 1) suggest positive selection, and ratios less 225 
than one suggest negative selection . We found evidence for positive selection at both time 226 
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points despite differences between subtypes (Fig. 2c). Separating mutations into mutational 227 
fractions demonstrated that shared but not private mutations showed positive dN/dS ratios in all 228 
three glioma subtypes indicating that only shared mutations (including truncal mutations) are 229 
likely subject to positive selection (Fig. 2c). The dN/dS ratio of initial-only mutations showed that 230 
these are neither positively nor negatively selected for, while recurrence-only mutations were 231 
subject to negative selection in IDHwt.  232 
To verify the reduced selective pressure in the private mutations we used an orthogonal 233 
method to test for evidence of selection (neutralitytestr)30. The method uses variant allele 234 
frequency distributions and estimated mutation rates to detect whether profiles significantly 235 
deviate from a model of neutral evolution (i.e. as depicted by a linear relationship in Fig. 2d). In 236 
accordance with dNdScv results, private mutations demonstrated dynamics consistent with 237 
neutral evolution (Fig. 2d). Shared subclonal mutations deviated from linearity and were 238 
consistent with selection both in non-hypermutators and hypermutators (Fig. 2d, Extended Data 239 
Fig. 6a-b), providing additional evidence that the strongest selective forces occur early in 240 
gliomagenesis. 241 
 Cohort-level analysis of selection masks the heterogeneity that exists in individual 242 
evolutionary trajectories. To determine the selective effects at each tumor time point we used a 243 
Bayesian framework (SubClonalSelection) which simultaneously provides sample-specific 244 
probabilities for both selection and neutrality while modeling sources of noise in sequencing 245 
data. The classification of a sample as “selection” or “neutral” is determined by whichever model 246 
has the greater probability. Classification as “neutral” reflects the accumulation of random 247 
mutations that are not subject to selection. Given the stringent algorithm requirements, 183 248 
patients were included in this analysis with at least one time point, and 104 patients with both 249 
time points (16 IDHmutant-codels, 29 IDHmutant-noncodels, 59 IDHwt, Supplementary Table 250 
3). Neutral to neutral was the most common evolutionary trajectory across all three subtypes 251 
(52%), and IDHwt tumors displayed the highest observed selection at any time point with 252 
selection detected in 64% of tumors (Fisher’s exact test P = 0.01, Fig. 2e, Supplementary Table 253 
3). IDHwt gliomas with evidence for selection at recurrence had a shorter overall survival than 254 
IDHwt gliomas classified as neutral at recurrence (P = 2.7E-02; log-rank statistic, Fig. 2f), 255 
suggesting that subclonal competition associates with more aggressive tumor behavior. To 256 
address the limitations of smaller sample sizes in the IDH-mutant subtypes, we performed a 257 
Cox proportional hazards model including age at first diagnosis, all three glioma subtypes, and 258 
mode of selection at recurrence. This analysis revealed that selection at recurrence was 259 
significantly associated with shorter survival across subtypes (HR = 1.53 95% CI 1.00-2.41, P = 260 
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4.8E-02, Supplementary Table 4). We next investigated whether radiation and chemotherapy 261 
imposed a selective effect, by comparing the evolutionary status at recurrence with treatment 262 
and other clinical variables. We did not observe significant associations between subclonal 263 
selection and radiation therapy or chemotherapy (Fisher’s exact-test P > 0.05, Supplementary 264 
Table 5), suggesting that standard therapeutic approaches for glioma have limited impact on the 265 
subclonal tumor architecture. While high-depth sequencing datasets may be required to detect 266 
subtle selective effects25, our analyses raise the possibility that the survival benefit derived from 267 
standard chemoradiation results from tumor cell elimination where treatment sensitivity of 268 
individual cells is not determined by genetic factors.  269 
Driver alteration frequencies across time 270 
We evaluated how stability, acquisition, and loss of mutation and copy number drivers4 over 271 
time impact glioma evolution. We used dNdScv to nominate 12 candidate mutation driver genes 272 
at both time points (Q < 0.05, Fig. 3a, Extended Data Fig. 7a) and determined significant copy 273 
number alterations that recapitulated previously identified drivers (Extended Data Fig. 7b). 274 
Mutations in IDH1 and co-occurring 1p/19q chromosome-arm loss have been suggested as 275 
glioma-initiating events14, which was corroborated by the observation that these events were 276 
never lost or acquired during the surgical interval (Fig. 3a, Extended Data Fig. 8a). Similarly, we 277 
observed that TERT promoter mutations were almost always shared in the IDHmutant-codel 278 
and IDHwt, though many samples lacked sufficient coverage in this GC-rich region. 279 
Chromosome 7 gains and chromosome 10 losses were present in a large majority of IDHwt 280 
initial tumors and persisted into recurrence.  281 
Shifts in the fraction of cancer cells harboring an event may also indicate a time 282 
dependency of drivers. We determined changes in cellular prevalence of shared driver events 283 
by ordering events in each sample by their CCF (Extended Data Fig. 9). ATRX mutations in 284 
IDHmutant-noncodel initial tumors demonstrated lower CCFs than TP53 (P = 0.03) and IDH1 (P 285 
= 0.10) mutations, suggesting IDH1 and TP53 mutations precede ATRX inactivation14. There 286 
was no difference in CCF between IDH1 and TP53 amongst initial gliomas (P = 0.98), however, 287 
IDH1 mutations demonstrated significantly lower CCFs compared with TP53 (P = 0.0018) in 288 
recurrent gliomas. We did not observe any CCF differences among driver mutations detected in 289 
IDHwt tumors at either time point. Chromosome 10 deletion CCFs were higher compared to 290 
chromosome 7 amplifications (P = 0.0036) implying that chromosome 10 deletions arise earlier 291 
31. Similarly, there was no difference in CCF between CDKN2A deletion and EGFR amplification 292 
(P = 0.70). EGFR and chromosomal arm events significantly differed (i.e. 10p del vs EGFR 293 
amp, P = 0.0019) but not CDKN2A deletion and chromosomal events (i.e. 10p del vs CDKN2A 294 
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del, P = 0.33). The consistently high CCF for EGFR amplifications could indicate that these 295 
events precede even some larger chromosomal aberrations, while not excluding the possibility 296 
that high levels of extrachromosomal EGFR 32 artificially inflate CCF. 297 
 Longitudinal changes in CCF values provide additional insights into evolutionary 298 
dynamics. For instance, the CCF value may increase when a driver event is linked to clonal 299 
expansion, or conversely, decrease when a clone is outcompeted. Most individual drivers did 300 
not demonstrate significant consistent CCF changes between the initial tumor and recurrence 301 
(Extended Data Fig. 10a). A notable exception was the TP53 mutation CCF that increased over 302 
time (P = 0.037) in IDHmut-noncodels, but not IDHwt gliomas (P = 0.13, Extended Data Fig. 303 
10b). We did not observe any differences in IDH1 CCF over time among IDHmut-noncodel 304 
tumors, possibly because the general trend of these tumors to increase in CCF is counteracted 305 
by the biological loss of relevance of mutant IDH1 over time (Extended Data Fig. 10c). Indeed, a 306 
gross comparison of all shared mutation CCFs revealed an increase in recurrent IDHmut-307 
noncodel tumors (P < 0.0001), which may reflect increased clonality and a reduction in 308 
intratumoral heterogeneity (Extended Data Fig. 10d). In contrast, shared CCFs decreased in 309 
IDHwt tumors, potentially indicating a general increase in intratumoral heterogeneity at 310 
recurrence (P < 0.0001, Extended Data Fig. 10d). We confirmed that IDHmutant-noncodel CCF 311 
increases and IDHwt decreases were not biased by patients with high mutation burden through 312 
the classification of patient-specific shared mutation CCF change (Extended Data Fig. 10e). 313 
We next investigated whether specific somatic alterations were acquired or lost over 314 
time. Gene-specific enrichment of many recurrence-only mutations was found in hypermutated 315 
tumors, but there was no enrichment for somatic gene alterations in non-hypermutators 316 
suggesting that glioma recurrence is not directed by particular sets of mutations (Extended Data 317 
Fig. 8b). Within subtypes we detected an enrichment in CDKN2A homozygous deletions (Fig. 318 
3a, Extended Data Fig. 8a) in recurrent IDHmutant-noncodels, which was corroborated by 319 
additional cell cycle gene alterations (focal gain of CCND2, CDK4, CDK6, and mutation or 320 
homozygous loss of RB1). Mutations in cell cycle checkpoint control genes are associated with 321 
genomic instability 33. Therefore, we analyzed aneuploidy levels by determining the proportion of 322 
the genome that had undergone aneuploidy events (Extended Data Fig. 11a-b). We observed 323 
that IDHmutant-noncodel tumors had a higher level of aneuploidy at recurrence (Wilcoxon rank 324 
sum test P = 1.4E-06 total aneuploidy, p = 8.6E-03 arm-level aneuploidy, Extended Data Fig. 325 
11c-d) with tumors carrying acquired cell cycle gene alterations displaying the largest increases 326 
in aneuploidy (P = 7.6E-06; Wilcoxon rank sum test, Fig. 3b). We reasoned that CDKN2A 327 
deletions may precede aneuploidy. Homozygous CDKN2A deletions had significantly higher 328 
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CCFs compared to average CNV CCF across the genome (as a surrogate for aneuploidy 329 
related copy number changes), suggesting that CDKN2A loss occurred prior to aneuploidy (Fig. 330 
3c). These alterations may hasten disease progression as patients with either cell cycle 331 
alterations or the largest increases in aneuploidy at recurrence demonstrated significantly 332 
shorter survival than patients without these alterations (log-rank test P < 0.0001, Fig. 3d). Taken 333 
together, the persistence of drivers over time and the paucity of consistent change imply that 334 
therapy does not result in selection of specific sets of molecular changes.  335 
Immunoediting activity in glioma 336 
We next investigated how the immune microenvironment affects evolutionary trajectories. The 337 
immune system may prune tumor cells carrying immunogenic (neo-)antigens, resulting in the 338 
selection of subclones capable of evading the immune response. Evidence of this 339 
immunoediting process has been shown in several cancer types, including glioma 34-37, and 340 
suggests active immunosurveillance that may be therapeutically exploited 38. We 341 
computationally predicted neoantigen-causing mutations39. As expected, the neoantigen load 342 
across the GLASS cohort was strongly correlated with exonic mutation burden (Spearman’s 343 
Rho = 0.89), with 42% of nonsynonymous exonic mutations giving rise to neoantigens on 344 
average. This fraction did not significantly differ by glioma subtype or between initial and 345 
recurrent tumors (P > 0.05, Wilcoxon rank-sum test; Fig. 4a). The most common neoantigen 346 
arose from the clonal R132H mutation in IDH1 and was present in of 22 out of 88 IDH-mutant 347 
initial and recurrent tumors. Beyond mutations in IDH1, no mutations gave rise to a neoantigen 348 
found in more than three tumors at a given timepoint (Supplementary Table 6). Across the 349 
dataset, neoantigens and non-immunogenic mutations exhibited similar changes in cancer cell 350 
fractions between initial and recurrent tumors indicating a lack of neoantigen-specific selection 351 
processes over time (Extended Data Fig. 12a). 352 
We then examined the extent to which immunoediting occurred by comparing each 353 
sample’s observed neoantigen rate to an expected rate that was empirically derived from our 354 
dataset. The output of this approach is a normally distributed set of ratios centered at 1. 355 
Samples with an observed-to-expected neoantigen ratio < 1 exhibit evidence of neoantigen 356 
depletion relative to the rest of the dataset, and thus are more likely to have been 357 
immunoedited. We found that none of the three glioma subtypes harbored observed-to-358 
expected ratios that significantly differed from 1 (P > 0.05, one sample t-test), though IDHwt 359 
tumors exhibited significantly lower scores compared to IDHmut-noncodels (t-test, P = 0.04; Fig. 360 
4b). We additionally did not observe an association between the observed-to-expected ratio and 361 
survival when adjusting for subtype and age (Wald test, P > 0.05), nor was there a difference 362 
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between samples with neutral evolution dynamics compared to those exhibiting evidence of 363 
subclonal selection. When comparing samples longitudinally, we found that the observed-to-364 
expected neoantigen ratio was strongly correlated between initial and recurrent tumors of each 365 
patient (Pearson’s R = 0.73, P = 5E-38), suggesting that the neoantigen depletion level in the 366 
recurrence reflects that of the initial tumor (Fig. 4c).  367 
Immunoediting is most likely to take place in the tumors with high cytolytic activity and 368 
low levels of immunosuppressive activity37. Hypermutators, which have high neoantigen loads, 369 
have previously been associated with highly cytolytic microenvironments 36. However, we did 370 
not observe any differences in the observed-to-expected neoantigen ratio between 371 
hypermutated recurrent tumors and their initial counterparts, nor did we observe differences 372 
between hypermutated and non-hypermutated recurrent tumors, indicating that immunoediting 373 
activity is not related to the total number of mutations in a sample (Wilcoxon rank-sum test P > 374 
0.05; Extended Data Fig. 12b). To more directly determine whether there were immunologic 375 
factors associated with neoantigen depletion, we analyzed CIBERSORT immune cell fractions 376 
from a subset of samples that had undergone expression profiling in a previous study (n = 84 377 
from 42 tumor pairs) 36,40. Initial tumors with an observed-to-expected neoantigen ratio >1 378 
exhibited significantly higher levels of CD4+ T cells than those with a ratio < 1, while recurrent 379 
tumors with a ratio > 1 exhibited significantly higher levels of macrophages, neutrophils, and 380 
significantly lower levels of plasma cells relative to those with ratio < 1 (P < 0.05, Wilcoxon rank-381 
sum test; Extended Data Fig. 12c).  382 
While we did not detect many factors associated with the observed-to-expected 383 
neoantigen ratio, we did observe that the ratio was significantly associated with the total number 384 
of unique HLA loci in a patient (Spearman’s Rho = 0.28, P = 2E-9), reflecting similar findings in 385 
lung cancer41. This may bias analyses comparing the ratio across patients. To determine 386 
whether immunoediting varies over time in a patient-agnostic manner, we compared the 387 
observed-to-expected neoantigen ratio derived from a sample’s clonal mutations, which likely 388 
arose earlier in tumor evolution, to that derived from their subclonal mutations, which likely 389 
arose later. We did not observe a significant difference in the observed-to-expected neoantigen 390 
ratio of each patient’s clonal and subclonal neoantigens, regardless of glioma subtype or 391 
whether the sample was an initial tumor or recurrence (P > 0.05, paired t-test; Fig. 4d). 392 
Together, these analyses suggest that neoantigens in glioma are not exposed to differing levels 393 
of selective pressure throughout their development.  394 
DISCUSSION 395 
12 
 
We reconstructed the evolutionary trajectories of 222 patients with glioma to better understand 396 
treatment failures and tumor progression. The longitudinal molecular profiles revealed common 397 
features such as acquired hypermutation and aneuploidy, but highlighted the individualistic 398 
paths of post-treatment glioma evolution. Our results provide evidence that current standard of 399 
care therapies do not frequently coerce glioma down predictable paths. Instead, an unexpected 400 
number of gliomas appeared to stochastically evolve following early driver events. We expect 401 
that continuing to profile patient tumors over time using comprehensive sequencing approaches 402 
will identify additional common evolutionary paths. Our results here highlight the exciting 403 
prospects of several ongoing efforts that may inform new glioma therapies.  404 
The observation that treatment-induced hypermutation occurred across subtypes, but 405 
did not confer a detrimental effect on patient survival leaves the clinical significance of glioma 406 
hypermutation uncertain20-23,26. Future analyses that consider the number of therapy cycles and 407 
MGMT DNA methylation status will help to elucidate factors that predispose tumors to 408 
hypermutation and identify therapies that effectively exploit this phenotype’s vulnerabilities (e.g., 409 
high mutation burden). Acquired cell cycle alterations and aneuploidy in recurrent IDHmut-410 
noncodel gliomas also provide a rationale to target these more aggressive phenotypes with 411 
CDK inhibitors42 or with compounds that disrupt microtubule dynamics43. Finally, our analyses 412 
revealed that immunoediting activity does not vary in glioma over time, though we did observe 413 
variation between individual patients. Additional molecular and immunological data are needed 414 
to fully understand the impact this variability has on glioma evolution and to devise therapies 415 
directed at a glioma’s immunogenicity16. To this end, we found that clonal neoantigens arising 416 
from the IDH1 R132H mutation persisted from the initial tumor into the recurrence, justifying 417 
neoantigen vaccine approaches as treatments for initial and recurrent glioma44,45. 418 
 Collectively, these findings help shape our perspective on what constitutes an optimal 419 
treatment, and what approaches would result in the greatest removal or killing of glioma cells 420 
possible. Genomic characterization efforts such as TCGA have greatly increased our 421 
understanding of glioma biology, but were limited to a single snapshot in evolutionary time. The 422 
GLASS resource provides a framework to study the patterns of glioma evolution and treatment 423 
response. 424 
 425 
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Data reporting No statistical methods were used to predetermine sample size.  496 
DNA sequencing and data collection The GLASS dataset consists of both unpublished and 497 
published sequencing data as outlined in Supplementary Table 1. Among the cohort were 498 
exomes from 436 glioma samples (200 patients), whole-genome from 165 glioma samples (78 499 
patients), with overlapping exome/whole-genome data on 78 glioma samples (38 patients). A 500 
matching germline sequence was available for all patients. The dataset includes 257 sets of at 501 
least two time-separated tumor samples, seventeen standalone recurrences, and 19 patients 502 
with at least two geographically distinct tumor portions. More specifically, the dataset includes 503 
exome or whole-genome sequencing data on 211 primary gliomas, 234 first recurrences, 32 504 
second recurrences, 11 third recurrences and one fourth recurrence (Supplementary Table 7). 505 
Newly generated whole genome sequencing data for the Chinese University of Hong Kong 506 
(HK), Northern Sydney Cancer Centre (NS) and MD Anderson Cancer Center (MD) cohorts 507 
were subjected to 150 base paired-end sequencing. The HK samples were sequenced using a 508 
HiSeqX while the NS and MD cohorts were sequenced using a NovaSeq according to Illumina’s 509 
protocols. Whole exome capture was performed using the following platforms as reported in 510 
previous publications. Agilent SureSelect Human All Exon 50Mb capture kit was used for 511 
patients SF-0001- SF-0021, Agilent SureSelect Human All Exon V4 capture kit was used for 512 
patients SF-0024 – SF-0029 in the UC San Francisco cohort. Agilent SureSelect Human All 513 
Exon v4 or v5 was used to capture samples in the Kyoto University cohort. Samsung Medical 514 
Center cohort reported using Agilent SureSelect kit for patients SM-R056 – SM-R071, SM-515 
R075, SM-R076, SM-R095- SM-R114 while Illumina TruSeq Exome-capture kit was used for 516 
patient SM-R072. Exome capture was performed using Agilent SureSelect Human All Exon 50 517 
Mb in The Cancer Genome Atlas (TCGA)-GBM cohort and Agilent SureSelect Human All Exon 518 
v2.0, 44Mb kit in the TCGA-LGG cohort. Columbia University cases were captured using Agilent 519 
V3 50M kit, sequencing 90bp PE for samples R009-TP, R009R1, R011TP, R011R1, R014TP, 520 
R014R1, R017-R1, R018-R1, R019-R1. Mapping files of initial tumor and normal samples of 521 
patients R017 – R019 were obtained from TCGA through CG-hub. All other samples were 522 
captured using Agilent SureSelect XT Human All Exon v4 Kit, PE, 80M reads, 150X on target 523 
coverage. Samples in the Henry Ford Hospital cohort were multiplexed and sequenced using 524 
Illumina HiSeq 2000 by the Sequencing and Microarray Facility at an average target exome 525 
coverage of 100× using 76-bp paired-end reads. Samples in the HK cohort were subjected to 75 526 
base paired-end sequencing for HK-0001 – HK-0004 as performed NextSeq in high output 527 
mode. In the Leeds Cohort (LU) SureSelectXT V5 kit (PE100) was used to construct exome 528 
libraries. Illumina TruSeq Exome capture kit was used for samples at the Medical University of 529 
Vienna – CeMM. 530 
GLASS identifiers A GLASS barcode system was created, based on TCGA barcode design, in 531 
an effort to de-identify patient information and provide an organized framework for the different 532 
pieces of the dataset. 533 
GLASS barcodes are composed of 24 characters. The first four characters specify the 534 
project (either GLSS or TCGA). All datasets submitted to the GLASS consortium, published and 535 
unpublished, were given the GLSS project ID. Samples that were part of the TCGA cohorts 536 
(TCGA GBM and TCGA LGG) were given a TCGA designation. The next two characters 537 
designate the center where the samples were either acquired or sequenced (Supplementary 538 
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Table 7). This is followed by the four-character center specific patient identification that was kept 539 
as close as possible to the patient identification provided by the collaborators to allow a 540 
simplified trace back process. Patient data is divided by a relative sample type, such as initial 541 
tumor (TP), recurrent tumor (R1), normal tissue (NB, NM, etc), or metastatic tumor sample (M1). 542 
If there was more than one recurrence the relative number was specified following “R”.  Some 543 
patients had surgeries for which a biospecimen was unavailable. Thus, a surgical number was 544 
also provided to indicate temporal ordering (Supplementary Table 8). To include spatially 545 
separated samples the portion designation was added, which is followed by one character 546 
specifying the type of analyte, either DNA (D) or RNA (R). As there is variation in the 547 
sequencing analysis, a three-character designation represents either whole genome (WGS) or 548 
whole exome sequencing (WXS). The last part of the GLASS barcode is a six-character 549 
designation unique to each barcode that was randomly generated.  550 
 551 
Computational pipelines All pipelines were developed using snakemake 5.2.2 46. Unless 552 
otherwise stated, all tools mentioned are part of the GATK 4 suite 47. All data was collected at a 553 
central location (The Jackson Laboratory) and was analyzed using homogenous pipelines 554 
capable of processing both raw fastq files as well as re-process previously analyzed bam files.  555 
Alignment and pre-processing Data pre-processing was conducted in accordance to the 556 
GATK Best Practices using GATK 4.0.10.1. Briefly, aligned BAM files were separated by read 557 
group, sanitized and stripped of alignments and attributes using ‘RevertSam’, giving one 558 
unaligned BAM (uBAM) file per readgroup. Uniform readgroups were assigned to uBAM files 559 
using ‘AddOrReplaceReadgroups’. Similarly, unaligned fastq files were assigned uniformly 560 
designated readgroup attributes and converted to uBAM format using 'FastqToSam'. uBAM files 561 
underwent quality control using 'FastQC 0.11.7'. Sequencing adapters were marked using 562 
‘MarkIlluminaAdapters’. uBAM files were finally reverted to interleaved fastq format using 563 
‘SamToFastq’, aligned to the b37 genome ('human_g1k_v37_decoy') using 'BWA MEM 0.7.17', 564 
attributes were restored using 'MergeBamAlignment'. 'MarkDuplicates' was then used to merge 565 
aligned BAM files from multiple readgroups and to mark PCR and optical duplicates across 566 
identical sequencing libraries. Lastly, base recalibration was performed using 'BaseRecalibrator' 567 
followed by 'ApplyBQSR'. Coverage statistics were gathered using 'CollectWgsMetrics'. 568 
Alignment QC was performed running 'ValidateSamFile' on the final BAM file and QC results 569 
were inspected using 'MultiQC 1.6a0' 48. A haplotype database for fingerprinting was generated 570 
using a modified version of the code on https://github.com/naumanjaved/fingerprint_maps. The 571 
tool ‘CrosscheckFingerprints’ was used to confirm that all readgroups within a sample belong to 572 
the same individual, and that all samples from one individual match. Any mismatches were 573 
marked and excluded from further analysis. 574 
Variant detection Variant detection was performed in accordance to the GATK Best practices 575 
using GATK 4.1.0.0. Germline variants were called from control samples using Mutect2 in 576 
artifact detection mode and pooled into a cohort-wide panel of normals. Somatic variants were 577 
subsequently called in individual tumor samples (single-sample mode) and in entire patients 578 
using GATK 4.1 Mutect2 in multi-sample mode. Mutect2 was given matched control samples, 579 
the aforementioned panel of normals and the gnomAD germline resource as additional controls. 580 
Cross-sample contamination was evaluated using ‘GetPileupSummaries’ and 581 
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‘CalculateContamination’ run for both tumor and matching control samples. Read orientation 582 
artifacts were evaluated using ‘CollectF1R2Counts’ and ‘LearnReadOrientationModel’. Somatic 583 
likelihood, read orientation, sequence context, germline and contamination filters were applied 584 
using ‘FilterMutectCalls’.  585 
Variant post-processing BCFTools 1.9 was used to normalize, sort and index variants49. A 586 
consensus VCF was generated from all variants in the cohort, removing any duplicate variants. 587 
The consensus VCF file was annotated using GATK 4.1 Funcotator and the v1.6.20190124s 588 
annotation data source. Allele frequencies (AFs) from multi-sample Mutect2 were used to 589 
compare AFs between related samples. Multi-sample Mutect2 calls and filters mutations across 590 
a patient as a whole and does not determine mutation calls in a single samples. Single-sample 591 
mutation calls were overlaid on the multi-sample calls to infer whether variants were called in 592 
individual samples. Single-sample called variants that were not present in the multi-sample 593 
callset were discarded.  594 
Mutational burden Mutational burden was calculated as the number of mutations per 595 
megabase (Mb) sequenced. A minimum coverage threshold of 15x was required for each base. 596 
DNA hypermutation was defined for recurrent tumors with greater than 10 mutations per Mb 597 
sequenced as these values were considered outliers (1.5 times the interquartile range above 598 
the upper quartile). Notably, there were a few initial gliomas that demonstrated a mutational 599 
frequency above 10 mutations per Mb. However, the “hypermutation” classification was 600 
restricted to only patients with this level at recurrence since these likely reflect different 601 
evolutionary paths. 602 
Mutational signatures The relative contributions of the COSMIC mutational signatures were 603 
determined from a patient’s initial-only, recurrence-only, and shared mutations by solving the 604 
non-negative-least squares (NNLS) problem for each set of mutations using the 30 signatures 605 
from version 2 (March 2015). Six signatures were dominantly enriched in at least 3% of the 606 
fractions and we resolved the NNLS using the reduced six-signature model to increase 607 
accuracy and reduce noise. 608 
Copy number segmentation Copy number identification was performed according to the 609 
GATK Best Practices and is outlined briefly here. The pipeline differs slightly for whole genomes 610 
and whole exomes. For genomes, the genome was segmented into 10kb bins using 611 
‘PreprocessIntervals’. For exomes, overlapping regions between several commonly used 612 
capture kits (Broad Human Exome b37, Nextera Rapid Capture, TruSeq Exome, SeqCap EZ 613 
Exome V3, Agilent SureSelect V4, Agilent SureSelect V7) were identified using ‘bedtools 614 
multiIntersectBed’. The tool ‘PreprocessIntervals’ was used to apply 1kb padding and to merge 615 
overlapping intervals. In parallel, ‘SelectVariants’ was used to subset the gnomAD resource of 616 
germline variants to variants with a population AF greater than 5%. Next, ‘CollectReadcounts’ 617 
was used to count reads in the bins generated by ‘PreprocessIntervals’ separately for 618 
autosomes and allosomes. In parallel, ‘CollectAllelicCounts’ was used to count reference and 619 
alternate reads at gnomAD variant sites with a population AF greater than 5%. The cohort was 620 
subsequently split into batches determined by sequencing center and 621 
‘CreateReadCountPanelOfNormals’ was used to create a panel of normal (PON) for each batch. 622 
PONs were created separately for allosomes and autosomes, and allosomes were separated 623 
further by sex. To further improve the panel of normals, GC content annotation of each interval 624 
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as determined by ‘AnnotateIntervals’ were given. Next, ‘DenoiseReadCounts’ was used to 625 
denoise the binned readcounts output by ‘CollectReadCounts’, given a PON determined by 626 
batch, chromosomes (allosomes or autosomes) and sex. Denoised copy ratios were plotted and 627 
inspected for quality concerns using ‘PlotDenoisedCopyRatios’. The tool ‘ModelSegments’ is an 628 
implementation of a gaussian-kernel binary-segmentation algorithm and was used to merge 629 
contiguous segments and assign copy and allelic ratios. The results of this segmentation were 630 
plotted using ‘PlotModeledSegments’ and inspected for quality concerns. 631 
 Copy number calling A copy number caller loosely based on GATK ‘CallCopyRatioSegments’ 632 
(which in turn is based off of ReCapSeg) and GISTIC was implemented to call both arm-level 633 
and high-level copy number changes, respectively50,51. 634 
 Segments (from ‘ModelSegments’) with a non-log2 copy ratio between 0.9 and 1.1 were 635 
determined to be neutral. These segments were then weighted by length and a weighted mean 636 
and standard deviation (sd) non-log2 copy ratio (once-filtered) were determined again. Outlier 637 
segments are removed and once again a weighted mean and sd non-log2 copy ratio (twice-638 
filtered) were determined. Segments with a non-log2 copy ratio between 0.9 and 1.1 and 639 
segments within two standard deviations of the twice-filtered mean were determined to be 640 
neutral, and segments outside of these boundaries were determined to have a low-level 641 
amplification or deletion, depending on the direction. 642 
 The weighted mean and sd of the non-log2 copy ratio (once-filtered) was then 643 
determined individually for each chromosome arm. Outlier segments were removed and the 644 
weighted mean and sd of the non-log2 copy ratio (twice-filtered) was determined again. In order 645 
to determine a high-level amplification and deletion threshold, the most highly amplified and 646 
deleted chromosome arms were selected, respectively. The twice-filtered mean plus (high level 647 
amplification) or minus (high level deletion) two times the sd of the selected arms were used as 648 
high-level thresholds. 649 
 Gene level copy number were called by intersecting the gene boundaries with the 650 
segment intervals and by calculating the weighted non-log2 copy ratio for that gene. The copy 651 
number call for that gene was then determined by comparing the gene-level non-log2 copy ratio 652 
to the previously determined thresholds. 653 
dNdScv The R package dNdScv52 (https://github.com/im3sanger/dndscv) was run using the 654 
default and recommended parameters for all mutations in initial tumor samples, recurrent tumor 655 
samples, and for each mutational fraction (unique to initial, unique to recurrent and shared). All 656 
analyses were conducted separately within the three main tumor subtypes.  657 
Aneuploidy calculation The most reductive metric of aneuploidy was computed by taking the 658 
size of all non-neutral segments divided by the size of all segments. The resulting aneuploidy 659 
value indicates the proportion of the segmented genome that is non-diploid. 660 
In parallel, an arm-level aneuploidy score modeled after a previously described method was 661 
computed53. Briefly, adjacent segments with identical arm-level calls (-1, 0 or 1) were merged 662 
into a single segment with a single call. For each merged/reduced segment, the proportion of 663 
the chromosome arm it spans was calculated. Segments spanning greater than 80% of the arm 664 
length resulted in a call of either -1 (loss), 0 (neutral) or +1 (gain) to the entire arm, or NA if no 665 
contiguous segment spanned at least 80% of the arm’s length. For each sample the number of 666 
arms with a non-neutral event was finally counted. The resulting aneuploidy score is a positive 667 
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integer with a minimum value of 0 (no chromosomal arm-level events detected) and a maximum 668 
value of 39 (total number of autosomal chromosome arms excluding the short arms for 669 
chromosomes 13, 14, 15, 21, and 22). 670 
Estimates of evolutionary pressures Evolutionary pressures were evaluated both by variant 671 
status and glioma subtype using the neutralitytestr algorithm as previously described (R-672 
package: neutralitytestr version: 0.0.2, https://github.com/marcjwilliams1/neutralitytestr)30. 673 
Individual variant allele frequency vectors were merged at the level of glioma subtype by variant 674 
status. Only mutations found in copy-neutral regions should were included in these analyses. 675 
For all else, default parameters were used. Merged VAF distributions were deemed to be 676 
selected when the neutral null hypothesis was rejected using several metrics. Tests for 677 
neutrality required that both R2 values < 0.98 and the area between the two curves of 1) merged 678 
VAF data and 2) a normalized distribution expected under neutrality to be significantly different. 679 
The SubclonalSelection algorithm was applied to GLASS mutation data to measure the 680 
selection strength in individual tumor samples (Julia package: SubclonalSelection, 681 
https://github.com/marcjwilliams1/SubClonalSelection.jl)15. Patients that had samples at both 682 
timepoints with a TITAN-defined purity estimate >= 0.5 and >= 25 subclonal mutations in non-683 
diploid regions were included. Mean coverage across all mutations was used as the 684 
“read_depth” input parameter and the model was run with the recommended 106 iterations and 685 
1000 particles. Samples were classified as neutral or selected based on the model that had the 686 
highest probability, in line with the prior applications to TCGA data15. Classification based on the 687 
highest model probability yielded stable results there was not a significant change in proportions 688 
when setting a higher classification probability threshold (P > 0.05, Pearson’s Chi-square test, 689 
for both probability thresholds of 0.6 and 0.7). At all three probability thresholds (0.5, 0.6, and 690 
0.7), Kaplan-Meier survival analyses between selection at recurrence and overall survival 691 
continued to indicate that patients with IDHwt tumors that were selected had a worse overall 692 
survival (P = 0.03 (n=81), P = 0.01 (n=66), P = 0.01 (n=56) respectively). 693 
Mutation clonality Each patient’s clonal architecture was inferred using PyClone (version 694 
0.13.1) by grouping SNVs into clonal clusters (https://github.com/aroth85/pyclone)54. The 695 
patient-level input mutation matrix was reduced by limiting to sites with at least 30x coverage 696 
across all samples. PyClone was subsequently ran using a binomial density model, connected 697 
initiation, and 10000 iterations. Sample purities were provided for each patient and parental 698 
copy number (minor and major allele counts) from TITAN were given. PyClone results were 699 
post-processed using a burn-in of 1000, thin of 1, minimum cluster size of 2 and a maximum 700 
number of clusters per patient of 12. Individual mutations were determined to be clonal if the 701 
PyClone cancer cell fraction (CCF) values were >= 0.5, subclonal for mutations with CCF >= 0.1 702 
and CCF <0.5, mutations were considered non-clonal when CCF < 0.1 as previously described 703 
55. 704 
CNV clonality Allele specific copy number, tumor purity and ploidy estimates were derived 705 
using a probabilistic model (TITAN, version 1.19.1) for both whole genome and whole exome 706 
sequencing samples 56. TITAN was supplied with the tumor denoised readcounts output by 707 
GATK DenoiseReadCounts and the tumor allelic counts at loci found to be heterozygous in 708 
control samples output by ModelSegments. An ‘alphaK’ (and ‘alphaKHigh’) parameter of 2500 709 
and 10000 was used for exomes and genomes, respectively. The patient sex was provided in 710 
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order to improve fitting allosomes. For each tumor-control pair TITAN was ran assuming an 711 
initial ploidy of two or three, and assuming 1 to 3 clusters, resulting in a total of six possible 712 
solutions per tumor/control pair. To select the optimal solution, TITAN’s internal selectSolution 713 
function was used with a threshold of 0.15 giving additional weight to diploid solutions. 714 
Timing analysis The CCF values output by TITAN or PyClone were used for separately timing 715 
copy number changes or mutations. To time specific copy number changes in genes, the 716 
average CCF for that gene was calculated. When timing mutations in genes, the highest CCF 717 
amongst the non-synonymous mutations was taken.  718 
Neoantigen analyses Neoantigens in this analysis were defined as all 8-11-mer peptides that 719 
arose from an exonic nonsynonymous SNV or indel and bound their respective patient’s HLA 720 
class I molecules at a binding affinity score (IC50) that was ≤ 500 nM and better than or equal to 721 
the wild-type form of the peptide. Each patient’s 4-digit HLA class I types were inferred using 722 
OptiType (version 1.3.1, https://github.com/FRED-2/OptiType) run on each patient’s matched 723 
normal sample57. VCF files for each tumor sample were annotated using Variant Effect Predictor 724 
(ensembl) with the Downstream and Wildtype plugins. Neoantigens from these VCFs were then 725 
called using pVACseq (version 4.0.10, https://github.com/griffithlab/pVAC-Seq)39 run using 726 
netMHCpan (version 2.8, http://www.cbs.dtu.dk/services/NetMHCpan-2.8/)58. For each 727 
pVACseq run, epitope length was set to 8, 9, 10, or 11, minimum binding affinity fold-change 728 
was set to 1, and downstream sequence length was set to full, with default parameters used for 729 
all other settings.  730 
Downstream neoantigen analyses were performed using the pVACseq output linked to its 731 
respective mutation information. Neoantigen-causing mutations were defined as all mutations 732 
that gave rise to at least one neoantigen. The observed-to-expected neoantigen ratio was 733 
calculated using a previously developed approach that compares each tumor’s observed 734 
neoantigen rate to an empirically derived expected rate that assumes no selection against 735 
neoantigen-causing mutations37: From the gold set samples in the GLASS cohort (n = 222), 736 
define ഥܰ௦ to be the expected number of nonsynonymous missense SNVs per synonymous SNV 737 
with trinucleotide context ݏ. ܤത௦	is then defined as the expected number of neoantigen-generating 738 
missense SNVs per nonsynonymous missense SNV with trinucleotide context ݏ. For a given 739 
sample ݅, define ௜ܻ as the sample’s set of synonymous SNVs and ݏ(݉) to be a synonymous 740 
SNV with trinucleotide context ݉. The expected number of nonsynonymous missense SNVs, 741 
௣ܰ௥௘ௗ, and neoantigen-causing mutations, ܤ௣௥௘ௗ, can then be calculated as follows:  742 
௣ܰ௥௘ௗ,௜ = ෍ ഥܰ௦(௠)
௠∈௒೔
 
ܤ௣௥௘ௗ,௜ = ෍ ഥܰ௦(௠)ܤത௦(௠)
௠∈௒೔
 
To obtain sample ݅’s final neoantigen depletion ratio ܴ௜, the observed number of neoantigen-743 
causing mutations in the sample, ܤ௢௕௦,௜ is divided by the sample’s observed number of 744 
nonsynonymous missense SNVs, ௢ܰ௕௦,௜, and then this ratio is divided by the ratio of ܤ௣௥௘ௗ,௜ and 745 
௣ܰ௥௘ௗ,௜. Thus: 746 
21 
 
ܴ௜ = 	
ܤ௢௕௦,௜ ௢ܰ௕௦,௜⁄
ܤ௣௥௘ௗ,௜ ௣ܰ௥௘ௗ,௜⁄
 
For analyses examining clonal/subclonal neoantigen ratios, the observed and expected 747 
numbers were calculated by subsetting a sample’s SNVs by the respective criteria and then 748 
recalculating the ratio as described above. To mitigate overfitting, all analyses presented here 749 
utilized samples from patients with at least 3 neoantigen-causing mutations in their primary and 750 
recurrent tumors.  751 
Immune cell analyses CIBERSORT relative immune cell fraction data used in downstream 752 
neoantigen analyses were downloaded from a previous publication36. 753 
Statistical methods All data analyses were conducted in R 3.4.2, Python 2.7.15, PostgreSQL 754 
10.5, and Julia 0.7. All survival analyses including Kaplan-Meier plots and Cox proportional 755 
hazards models were conducted using the R packages survival and survminer. 756 
Data availability All deidentified, non-protected access somatic variant profiles and clinical data 757 
are accessible via Synapse (http://synapse.org/glass). Raw data of the various sequencing 758 
datasets can be obtained per the overview provided in the Supplement.  759 
Code availability All custom scripts and pipelines are available on the project’s github page 760 
(https://github.com/TheJacksonLaboratory/GLASS). 761 
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 903 
Figure Legends 904 
Fig. 1 | Temporal changes in glioma mutational burden and processes. a. Each column 905 
represents a single patient (n = 222) at two separate timepoints grouped by glioma subtype and 906 
ordered left-to-right by decreasing mutation frequency at recurrence. Top, mutation frequency 907 
differences between initial and recurrent tumors. Blue dotted line indicates increased mutation 908 
frequency while a red dotted line indicates decreased mutational frequency. Stacked bar plot 909 
reflects the proportion of total mutations shared (mustard), private to initial (magenta), or private 910 
to recurrence (blue). Clinical information including hypermutation status, therapy, and grade 911 
changes. b. Stacked bar plot (n=219) indicating the dominant mutational signature among initial, 912 
recurrent and shared mutation fractions stratified by glioma subtype. c. The proportion of glioma 913 
recurrences with alkylating agent-related hypermutation, grouped by glioma subtype. Fisher’s 914 
exact test was used to compare proportions between subtypes. d. Kaplan-Meier curve depicting 915 
overall survival in hypermutant (red) versus non-hypermutant (blue) alkylating agent treated 916 
patients amongst IDHwt (left, n = 99) and IDHmut-noncodel (right, n = 32) tumors. Log-rank test 917 
P-values are shown. 918 
Fig. 2 | Quantifying selective pressures during glioma evolution. a. Schematic depiction of 919 
cancer cell fraction (CCF) values during tumor evolution indicating clonality and associated 920 
relative timing. b. Comparison of PyClone clusters ranked by CCF in matched initial and 921 
recurrent tumors. c. Left: dN/dS ratio for all variants (i.e. global) in initial and recurrent tumors 922 
for each subtype. Hypermutators were not included (n = 187). Dots represent the global dN/dS 923 
25 
 
ratio with associated Wald confidence intervals. Right: global dN/dS ratios for variant fractions 924 
per subtype. d. Cumulative distribution of subclonal mutations by their inverse variant allele 925 
frequency. Mutations were separated by timepoint, variant fraction, and glioma subtype. 926 
Deviation from a linear relationship, significant Kolmogorov-Smirnov P-values and R2 below 927 
0.98 indicate selection. e. Sankey plot indicating the breakdown of SubClonalSelection 928 
evolutionary modes by subtype and therapy (n = 104). The sizes of the bands reflect sample 929 
sizes and band colors highlight the glioma subtype. Gray coloring reflects instances when 930 
treatment information was not available. f. Kaplan-Meier curve showing survival differences 931 
between IDHwt recurrent tumors demonstrating selection (n = 39) compared with neutrally 932 
evolving tumors (n = 44). Log-rank P-value is indicated. 933 
Fig. 3 | Patterns of glioma driver frequencies over time. a. Driver dynamics for SNVs 934 
nominated by the dNdScv and CNVs nominated by GISTIC (n = 222). Each column represents 935 
a single patient at two separate time points stratified by subtype and ordered left-to-right by the 936 
number of driver alterations. The degree of aneuploidy difference (recurrence – initial) offers a 937 
summary metric for increases (> 0) or decreases (< 0) in aneuploidy at recurrence. Variants are 938 
marked and different shapes indicate whether a variant was shared or private. The variant type 939 
is depicted by its color. Stacked bar plots accompanying each gene/arm provide cohort-level 940 
proportions for whether the alteration was shared, lost, or acquired. b. Aneuploidy comparison 941 
in matching initial and recurrent IDHmut-noncodel tumors. c. Within-sample CCF comparison of 942 
CDKN2A homozygous deletion (homdel) to genome-wide CCF as a proxy for aneuploidy. A 943 
relative higher CCF indicates temporal precedence. Wilcoxon signed-rank test P-value is 944 
indicated. d. Kaplan-Meier curve comparing survival in IDHmut-noncodel tumors with an 945 
alteration in the cell cycle, acquired aneuploidy, or both (shades of red) versus unaltered 946 
IDHmut-noncodel tumors (blue). Log-rank P-value is shown. 947 
Fig. 4 | Neoantigen selection during tumor progression. a. Mean proportion of coding 948 
mutations giving rise to neoantigens (neoantigens/nonsynonymous) stratified by glioma subtype 949 
and timepoint (n = 222). Error bars represent standard deviation. b. Boxplot depicting the 950 
distribution of observed to expected neoantigen ratios in the GLASS cohort stratified by glioma 951 
subtype. P-value was calculated using the Wilcoxon rank-sum test. Each box spans quartiles, 952 
with the lines representing the median ratio for each group. Whiskers represent absolute range, 953 
excluding outliers. c. Scatterplot depicting the association between the observed-to-expected 954 
neoantigen ratio in a patient’s initial versus recurrent tumor. Each point represents a single 955 
patient. R represents Pearson correlation coefficient. Panels b and c only include samples with 956 
at least 3 neoantigens in the initial and recurrent tumors (n = 131, 63, and 24 for IDHwt, 957 
IDHmut-noncodel, and IDHmut-codel, respectively). d. Ladder plot depicting the difference in 958 
observed-to-expected neoantigen ratio between a tumor’s clonal and subclonal neoantigens. 959 
Each set of points connected by a line represents one tumor. Tumors are stratified by whether 960 
they were a patient’s initial or recurrent tumor. Lines are colored by each patient’s glioma 961 
subtype. Panel d only includes samples with at least 3 clonal neoantigens and at least 3 962 
subclonal neoantigens in both the initial and recurrent tumors (n = 35, 20 and 9 for IDHwt, 963 
IDHmut-noncodel, and IDHmut-codel, respectively). P-value was calculated using a paired two-964 
sided t-test. Colors in each panel represent the glioma subtype and are denoted at the bottom of 965 
the figure. 966 
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Extended Data Fig. 1 | Sample Selection. a. Quality control workflow steps identifying all 967 
GLASS samples available as a resource and the identification of the highest quality set of 968 
patient pairs (n = 222) used for the presented mutational and copy number analyses. b. 969 
Additional available datasets. 970 
Extended Data Fig. 2 | Mutation burden by time point and subtype. a. Boxplots and paired 971 
lines depicting coverage adjusted mutation frequencies in initial and matched recurrent samples 972 
across three subtypes. Wilcoxon signed-rank test P-values and sample sizes are indicated. b. 973 
Bee swarm plot depicting coverage adjusted mutation frequencies in fractions by subtype. 974 
Dashed line indicates the mean. One-way ANOVA P-values comparing three subtypes are 975 
indicated. c. Scatter plot showing the relationship between age at diagnosis and coverage 976 
adjusted mutation burdens by subtype and fraction. Linear model P-values are indicated and 977 
were adjusted by subtype. d. Similar to the analysis presented in c, but showing the relationship 978 
between time to recurrence and coverage adjusted mutation burdens. 979 
Extended Data Fig. 3 | Mutational signatures by fraction and subtype. a. Correlation plot 980 
showing the Pearson’s chi-squared (X2) residuals for each signature by fraction and subtype. A 981 
X2 was performed for each subtype and P-values are indicated. Positive residuals (blue) 982 
indicate a positive correlation, whereas negative residuals (red) indicate an anticorrelation. The 983 
point size reflects the contribution to X2 estimate. b. The same ordered of patients as Fig. 1a 984 
along with relevant clinical information is provided alongside the fraction-specific mutational 985 
signatures. PyClone mutational clusters are also presented.  986 
Extended Data Fig. 4 | Hypermutator clonality. a. Bar plots represent counts of recurrence-987 
only mutations per hypermutator tumor that were known to receive alkylating agent therapy and 988 
were successfully run through the PyClone algorithm. Colors indicate mutation clonality and 989 
color intensity indicates whether the mutations resulted in coding changes. b. Kaplan-Meier 990 
curve comparing alkylating agent-treated patients with IDHmut-noncodel hypermutator tumors 991 
that were predominantly clonal (n = 8), predominantly subclonal (n = 7), versus IDHmut-992 
noncodel non-hypermutators known to be treated with alkylating agents and had available 993 
PyClone data (n = 17). Log-rank P-value is shown. 994 
Extended Data Fig. 5 | Clonal structure evolution over time. a. The minimum cancer cell 995 
fraction of the most persistent (shared between initial and recurrence) PyClone cluster. b. 996 
Comparison of PyClone clusters ranked by CCF in matched initial and recurrent tumors, as Fig. 997 
2b but separated by subtype. c-d. Examples of cluster CCF dynamics over time in three 998 
separate samples, including (c) two multi-timepoint samples (d) and one multi-sector sample. 999 
These additional data are available in the GLASS resource, but only two time-separated 1000 
samples were used throughput the manuscript to ensure clarity. 1001 
Extended Data Fig. 6 | Variant allele fraction distribution (a) Non-hypermutator variant allele 1002 
fraction distributions for copy neutral variants in coding regions (n = 181 patients). Variants are 1003 
separated by subtype, fraction, and also whether the variant was non-synonymous or 1004 
synonymous mutation in a coding region. R2 goodness-of-fit measure and associated P-values 1005 
are shown for both mutation types. Note that this data considers only the coding portion of 1006 
genome while Fig. 2d presents both coding and non-coding. (b) The cumulative distribution of 1007 
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the subclonal mutations in copy-neutral regions for hypermutators (n = 31 patients). For each 1008 
variant fraction and subtype, the R2 goodness-of-fit measure and P-values are shown.  1009 
Extended Data Fig. 7 | Driver gene nomination. a. Local (gene-wise) dNdScv estimates by 1010 
subtype (rows) and fraction (columns). Genes are sorted by Q-value and P-value. The Q-value 1011 
is shown in color, whereas the P-value is indicated in light gray. The Q-value threshold of 0.05 is 1012 
indicated by a horizontal red line. b. GISTIC significant amplification (red) and deletion (blue) 1013 
plots in initial (left) and recurrent tumors (right). Chromosomal locations are ordered on the y-1014 
axis, Q-values are shown on the x-axis, and selected drivers are indicated by their chromosomal 1015 
location on the right. 1016 
Extended Data Fig. 8 | Driver acquisition over time a. Tabulated numbers of SNV (top) and 1017 
CNV (bottom) driver events that were shared, initial-only, or recurrence-only. P-values were 1018 
obtained using a two-sided Fisher test comparing the initial-only fraction to the recurrence-only 1019 
fraction testing for acquisition. b. One-sided Fisher test comparing the initial-only fraction to the 1020 
recurrence-only fraction amongst previously implicated glioma drivers testing for driver 1021 
acquisition. P-values were adjusted for multiple testing using the FDR (x-axis). Hypermutators 1022 
(red) and non-hypermutators (black) were separately analyzed. 1023 
Extended Data Fig. 9 | Intra-tumor CCF comparison. Ladder plots comparing the CCF of co-1024 
occurring drivers in single tumor samples. The color of the lines and points indicates whether 1025 
the sample shown is an initial (brown) or recurrent (green) tumor. Two-sided Wilcoxon rank-sum 1026 
test P-values are shown for all initial samples, all recurrent samples, as well as all samples 1027 
(black). 1028 
Extended Data Fig. 10 | Between time point intra-patient CCF comparison. a. Driver-gene 1029 
CCF comparison between initial and matched recurrences. Lines are colored by variant 1030 
classification. Two-sided Wilcoxon rank-sum test P-values are shown. b. TP53 CCF by subtype, 1031 
otherwise as in (a). c. IDH1 CCF by subtype, otherwise as in (a). d. Ladder plot visualizing CCF 1032 
change across all SNVs between initial and recurrent tumors, separated by subtype. Wilcoxon 1033 
rank-sum test was used to test for differences between time points. e. Initial and recurrent 1034 
mutations in each patient were compared using a Wilcoxon rank-sum test. Bar plot with counts 1035 
of patients in each subtype are shown. Patients lacking significant change are shown in yellow, 1036 
those with a significant increase or decrease are shown in dark and light blue, respectively. 1037 
 1038 
Extended Data Fig. 11 | Aneuploidy calculation a. Heatmap displaying the chromosomal 1039 
arm-level events (x-axis) with patients represented in each row. Patients are placed in the same 1040 
order for both the initial (left) and recurrence (right). White space was inserted as a break 1041 
between the three subtypes. b. Distribution of total aneuploidy difference. Acquired aneuploidy 1042 
determination (upper-quartile) indicated with a red line. c. Comparison of aneuploidy score 1043 
between initial and recurrent tumors separated by subtype d. As (c), comparing aneuploidy 1044 
value. 1045 
28 
 
Extended Data Fig. 12 | Neoantigen evolution and cellular analysis a. Bar plots 1046 
representing the number of shared mutations that give rise to neoantigens (top row, 1047 
“immunogenic”) and those that do not give rise to neoantigens (bottom row, “non-immunogenic”) 1048 
stratified by longitudinal clonality (“(clonality in initial)-(clonality in recurrence)”) and further 1049 
separated by subtype. Percentage of longitudinal clonality per subtype and mutation 1050 
immunogenicity are presented above the respective bars. b. Left: Ladder plot depicting the 1051 
difference in observed-to-expected neoantigen ratio between the initial and recurrent tumors of 1052 
patients with hypermutated tumors at recurrence. Each set of points connected by a line 1053 
represents one tumor (n  = 70). Right: Boxplot depicting the distribution of observed to expected 1054 
neoantigen ratios in recurrent tumors stratified by hypermutator status (n = 35 and 183 for 1055 
hypermutators and non-hypermutators, respectively). Each box spans quartiles, with the lines 1056 
representing the median ratio for each group. Whiskers represent absolute range, excluding 1057 
outliers. P-values for panel b were calculated using a paired and unpaired two-sided t-test, 1058 
respectively. c. Stacked bar plots depicting the average relative fraction of 11 CIBERSORT cell 1059 
types in the neoantigen depleted (< 1) and non-depleted (> 1) initial and recurrent tumor 1060 
subgroups. Asterisks to the right of each plot indicate a significant difference (P < 0.05, 1061 
Wilcoxon rank-sum test) between the depleted and non-depleted groups for the noted cell type 1062 
at that time.  1063 
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